Details of Disease

General Information of Disease (ID: DIS1H502)

Disease Name Estrogen-receptor positive breast cancer
Synonyms oestrogen receptor positive breast cancer; ER+ breast cancer; estrogen receptor positive breast cancer
Definition A subtype of breast cancer that is estrogen-receptor positive
Disease Hierarchy
DIS7DPX1: Breast cancer
DISGN7ZY: Breast carcinoma by gene expression profile
DIS1H502: Estrogen-receptor positive breast cancer
Disease Identifiers
MONDO ID
MONDO_0006512
UMLS CUI
C2938924
MedGen ID
1843470

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 3 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anastrozole DMNP60F Approved Small molecular drug [1]
Goserelin DMAT8CG Approved Small molecular drug [2]
Letrozole DMH07Y3 Approved Small molecular drug [3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 67 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ERBB4 TTWALCO Limited Altered Expression [4]
CTSD TTPT2QI Disputed Biomarker [5]
FOSL1 TTY8LZG Disputed Altered Expression [6]
GPER1 TTDSB34 Disputed Altered Expression [7]
HOXB13 TTZ6I58 Disputed Biomarker [8]
HSP90AB1 TTH5YN2 Disputed Biomarker [9]
KDM5B TTCLI75 Disputed Altered Expression [10]
SPDEF TT2ZUPY Disputed Biomarker [11]
TOP2A TTCGY2K Disputed Altered Expression [12]
ZNF217 TTY3BRA Disputed Altered Expression [13]
CCNE2 TTLDRGX moderate Altered Expression [14]
AOC3 TT7HC21 Strong Biomarker [15]
AR TTKPW01 Strong Altered Expression [16]
AREG TT76B3W Strong Biomarker [17]
ASPH TT2KHP7 Strong Altered Expression [18]
CDC20 TTBKFDV Strong Altered Expression [19]
CDK4 TT0PG8F Strong Biomarker [20]
CDK8 TTBJR4L Strong Biomarker [21]
CHKA TT10AWB Strong Altered Expression [22]
COL18A1 TT63DI9 Strong Genetic Variation [23]
CPA1 TT3LJ6G Strong Biomarker [24]
CRHR2 TTIY658 Strong Altered Expression [25]
CRY2 TTAO58M Strong Altered Expression [26]
CXXC5 TTVS4C3 Strong Altered Expression [27]
CYP2D6 TTVG215 Strong Genetic Variation [28]
E2F2 TT5FYX0 Strong Altered Expression [29]
EREG TTYSB89 Strong Biomarker [30]
ESRRG TT9ZRHB Strong Biomarker [31]
FGF10 TTNPEFX Strong Genetic Variation [32]
FGF7 TTFY134 Strong Biomarker [33]
GRPR TTC1MVT Strong Biomarker [34]
HSD17B1 TTIWB6L Strong Genetic Variation [35]
HSF1 TTN6STZ Strong Altered Expression [36]
HSPB8 TTY0OJN Strong Biomarker [37]
IRS1 TTAJSQ0 Strong Biomarker [38]
LHCGR TT2O4W9 Strong Biomarker [39]
LYN TT1RWNJ Strong Genetic Variation [40]
MAP3K1 TTW8TJI Strong Biomarker [39]
MAP3K11 TTETX6Q Strong Biomarker [41]
MAP4K4 TT6NI13 Strong Genetic Variation [42]
MSI2 TTTXQF6 Strong Altered Expression [43]
PCSK6 TT75LN9 Strong Biomarker [44]
PPARGC1B TTKSQ3W Strong Biomarker [45]
PPIF TTRFQTB Strong Altered Expression [31]
PRCP TTTJZ4M Strong Biomarker [46]
PTK6 TT6TH8V Strong Altered Expression [47]
PTPN14 TTNIR6C Strong Genetic Variation [48]
RPS6KA1 TTIXKA4 Strong Biomarker [49]
SLC19A1 TT09I7D Strong Genetic Variation [23]
SLC6A14 TTB6H2S Strong Biomarker [50]
SLCO2B1 TTDL3UZ Strong Altered Expression [51]
SPHK1 TTOHFIY Strong Biomarker [52]
STC2 TT4EFTR Strong Altered Expression [53]
TK1 TTP3QRF Strong Altered Expression [54]
TRIM28 TTQ2BKV Strong Biomarker [55]
TRIP10 TTKHTGE Strong Biomarker [56]
WNT7A TT8NARC Strong Altered Expression [57]
WWP1 TTBWMKT Strong Biomarker [58]
AGR2 TT9K86S Definitive Biomarker [59]
BMP6 TT07RIB Definitive Biomarker [60]
CDK3 TTMYWL7 Definitive Biomarker [61]
CETP TTFQAYR Definitive Genetic Variation [62]
FES TTLBY21 Definitive Biomarker [63]
MYB TT8V13P Definitive Biomarker [64]
OSM TTIVXSE Definitive Biomarker [65]
PDE4D TTSKMI8 Definitive Biomarker [66]
RPS6KA6 TT3KYWB Definitive Posttranslational Modification [67]
------------------------------------------------------------------------------------
⏷ Show the Full List of 67 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC20A1 DTMULXV Strong Biomarker [68]
------------------------------------------------------------------------------------
This Disease Is Related to 6 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
UGT2B15 DENZ6B1 Disputed Genetic Variation [69]
AKR1C1 DE7P2FB Strong Biomarker [39]
HSD17B7 DEDMWFX Strong Altered Expression [70]
NAT1 DE7OAB3 Strong Altered Expression [71]
UBASH3B DE10BJ5 Strong Biomarker [72]
UGT2B17 DEAZDL8 Strong Genetic Variation [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
This Disease Is Related to 120 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
CCN5 OTADU8JJ Disputed Biomarker [74]
KLF5 OT1ABI9N Disputed Altered Expression [75]
PELP1 OTVXQNOT Disputed Biomarker [76]
RAB27B OTPF9D0K Disputed Biomarker [77]
S100A7 OTJFVJRF Disputed Biomarker [78]
TADA3 OTNUAIO9 Disputed Altered Expression [79]
ADAM29 OTGLTTKU Strong Genetic Variation [80]
ADAMTS2 OTTK22NO Strong Altered Expression [26]
ADO OTRLGQ7V Strong Genetic Variation [81]
ADRM1 OTOU4EY6 Strong Biomarker [82]
AGFG1 OTI8ZKC4 Strong Biomarker [83]
ALX3 OTXZ25PZ Strong Biomarker [84]
ANKLE2 OTHCYR6Y Strong Altered Expression [85]
APOBEC3B OTHLNI51 Strong Altered Expression [86]
BARD1 OTTC0Z9Y Strong Altered Expression [87]
BCAS2 OTRMF2WY Strong Altered Expression [88]
BTG2 OTZF6K1H Strong Altered Expression [89]
CBFB OTIAC6W4 Strong Genetic Variation [23]
CCDC170 OTNQOJ6S Strong Biomarker [90]
CCDC6 OTXRQDYG Strong Biomarker [91]
CENPA OT0NEJ4X Strong Biomarker [92]
CENPI OTWRIMZ3 Strong Altered Expression [93]
CHP1 OTHTXN1A Strong Biomarker [94]
CITED2 OT812TV7 Strong Biomarker [95]
CRB3 OTQKPTMU Strong Biomarker [96]
CYC1 OT0962IM Strong Biomarker [97]
CYP4Z1 OTKRGJBG Strong Altered Expression [98]
DCAF1 OT3ZDVOE Strong Biomarker [83]
DCTN3 OTQOSUES Strong Biomarker [94]
DDX17 OTXRMMBP Strong Biomarker [99]
DLX4 OTLWVCN4 Strong Biomarker [100]
DPP3 OTUIVL1C Strong Altered Expression [101]
DUSP7 OT6Z5AHP Strong Altered Expression [102]
DYNC1H1 OTD1KRKO Strong Biomarker [94]
E2F7 OTWW358N Strong Altered Expression [103]
E2F8 OTQKZGFP Strong Altered Expression [104]
ECT2 OTQDUCT6 Strong Biomarker [105]
EIF3F OTU20K6L Strong Altered Expression [106]
EIF4A1 OTMTBX6N Strong Biomarker [107]
EIF4B OTE8TXA8 Strong Biomarker [107]
EPN3 OTNNYDT6 Strong Altered Expression [108]
EPRS1 OTXK0FLB Strong Biomarker [109]
ERLIN2 OT551BVG Strong Biomarker [110]
ESRP1 OTNCS4SL Strong Biomarker [111]
FBXL22 OTOT7JCD Strong Genetic Variation [112]
FKBPL OTR9ND6K Strong Biomarker [113]
FLOT2 OTZ0QR5L Strong Biomarker [114]
FOXA1 OTEBY0TD Strong Altered Expression [115]
G0S2 OT8FL49L Strong Altered Expression [116]
GARS1 OT5B6R9Y Strong Posttranslational Modification [117]
GFRA1 OT3WBVYB Strong Biomarker [118]
GGNBP2 OT7K9YZV Strong Biomarker [119]
HEATR6 OTD3MYS0 Strong Biomarker [120]
HOXB3 OT9UC5PE Strong Biomarker [121]
HOXB5 OTU74TB8 Strong Altered Expression [122]
IGFBP4 OT2HZRBD Strong Altered Expression [123]
IKBKE OT5VYOSM Strong Altered Expression [124]
IL17RB OT0KDNSF Strong Biomarker [125]
JMJD6 OTILR7E4 Strong Altered Expression [126]
KIF17 OTHASX9G Strong Altered Expression [127]
KIF18A OTSMBJ24 Strong Biomarker [128]
KIF23 OTY850JC Strong Biomarker [129]
LAMTOR5 OTER0U8L Strong Biomarker [8]
MGP OTZWU3FU Strong Altered Expression [130]
MRPS30 OTDXIAGG Strong Genetic Variation [32]
NCOA1 OTLIUJQD Strong Biomarker [131]
NCOR2 OTY917X0 Strong Biomarker [95]
NNAT OTNRLO7G Strong Altered Expression [132]
NR2E3 OTO3GBHQ Strong Altered Expression [133]
OCIAD1 OTJBY7PV Strong Biomarker [134]
ORAI3 OTUP3OH3 Strong Biomarker [135]
PADI2 OTT40K94 Strong Biomarker [136]
PDHA2 OT9D9T2F Strong Biomarker [137]
PHB2 OTCAX3AW Strong Biomarker [94]
PHLDA1 OTFTWMIQ Strong Biomarker [138]
PIAS3 OT3TWH9R Strong Altered Expression [133]
PITPNB OTNM6T78 Strong Genetic Variation [23]
PRKAG3 OTS1A2VE Strong Genetic Variation [139]
PRMT2 OT63JZCI Strong Altered Expression [140]
PTTG1IP OTX21QTE Strong Genetic Variation [141]
RAB31 OTMLXQZ0 Strong Altered Expression [142]
RAI2 OTR8LX4J Strong Biomarker [143]
RASAL2 OTGMMX6W Strong Altered Expression [144]
RBBP8 OTRHJ3GI Strong Altered Expression [145]
RBFOX2 OTXY1WVH Strong Genetic Variation [146]
RBM38 OTPO8EXU Strong Altered Expression [147]
RBP2 OTR8QG5V Strong Biomarker [148]
RGCC OTYJMLWM Strong Altered Expression [128]
RNF168 OT6AZXX8 Strong Biomarker [149]
RPAIN OTBMXAYK Strong Biomarker [83]
SDCBP OTS3NCC5 Strong Biomarker [150]
SEPTIN4 OTD16B30 Strong Biomarker [151]
SETD1A OTVVWRIC Strong Biomarker [152]
SFMBT2 OTZQT61Q Strong Genetic Variation [23]
SGK3 OTQ6QO99 Strong Biomarker [153]
SGSM2 OTWQR9IL Strong Biomarker [154]
SHARPIN OTU1J2KH Strong Biomarker [155]
SHOX2 OTLCZZJW Strong Altered Expression [156]
SIAH2 OTKED2XN Strong Genetic Variation [157]
SIPA1 OTXY5RXC Strong Biomarker [158]
SIRT4 OT5S0J23 Strong Biomarker [159]
SLU7 OTZUUICN Strong Biomarker [111]
SRARP OTR3TNTJ Strong Biomarker [160]
SRSF6 OTGLOSYE Strong Altered Expression [25]
ST3GAL1 OTFCO8QX Strong Biomarker [118]
STAT5B OTZVPEBT Strong Biomarker [161]
TARBP2 OT1QQ8H3 Strong Altered Expression [162]
TAS2R38 OTX5MM36 Strong Biomarker [91]
TFF3 OTJJDRTU Strong Biomarker [163]
TMEM14A OTANQA6G Strong Genetic Variation [42]
TMPO OTL68EL4 Strong Biomarker [164]
TOX3 OTC9NR4W Strong Genetic Variation [165]
TRIM25 OT35SG1R Strong Altered Expression [75]
TRIM29 OT2DNESG Strong Altered Expression [166]
AXIN1 OTRGZGZ5 Definitive Biomarker [167]
BAG1 OTRQNIA4 Definitive Altered Expression [168]
CIP2A OTVS2GXA Definitive Altered Expression [169]
KMT2C OTC59BCO Definitive Genetic Variation [170]
MASTL OTQ7YKK5 Definitive Altered Expression [171]
NUS1 OT4DQ82L Definitive Biomarker [172]
------------------------------------------------------------------------------------
⏷ Show the Full List of 120 DOT(s)

References

1 Anastrozole FDA Label
2 Goserelin FDA Label
3 Letrozole FDA Label
4 HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.Breast Cancer Res. 2018 Nov 20;20(1):139. doi: 10.1186/s13058-018-1072-1.
5 Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter.Mol Endocrinol. 1998 Sep;12(9):1310-21. doi: 10.1210/mend.12.9.0159.
6 Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.J Cancer Res Clin Oncol. 2015 Oct;141(10):1715-26. doi: 10.1007/s00432-015-1925-2. Epub 2015 Feb 10.
7 GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.Int J Oncol. 2017 Oct;51(4):1191-1198. doi: 10.3892/ijo.2017.4117. Epub 2017 Sep 5.
8 Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.J Hematol Oncol. 2018 Feb 23;11(1):26. doi: 10.1186/s13045-018-0577-5.
9 Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection.PLoS One. 2015 Jan 24;10(1):e0117058. doi: 10.1371/journal.pone.0117058. eCollection 2015.
10 The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.Cell Rep. 2014 Jan 30;6(2):325-35. doi: 10.1016/j.celrep.2013.12.021. Epub 2014 Jan 9.
11 Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy.PLoS One. 2016 Dec 20;11(12):e0168770. doi: 10.1371/journal.pone.0168770. eCollection 2016.
12 TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.Breast Cancer Res Treat. 2012 Jul;134(2):751-7. doi: 10.1007/s10549-012-2112-7. Epub 2012 Jun 16.
13 Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.BMC Genomics. 2014 Jun 24;15(1):520. doi: 10.1186/1471-2164-15-520.
14 Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2009 Feb;42(2):87-103. doi: 10.1677/JME-08-0076. Epub 2008 Nov 4.
15 Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.Int J Mol Sci. 2017 Dec 20;18(12):2775. doi: 10.3390/ijms18122775.
16 Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z.
17 Bisphenol AF promotes estrogen receptor-positive breast cancer cell proliferation through amphiregulin-mediated crosstalk with receptor tyrosine kinase signaling.PLoS One. 2019 May 6;14(5):e0216469. doi: 10.1371/journal.pone.0216469. eCollection 2019.
18 Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate--hydroxylase expression.Cancer Sci. 2017 Dec;108(12):2454-2461. doi: 10.1111/cas.13416. Epub 2017 Oct 21.
19 CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.Breast Cancer Res Treat. 2019 Dec;178(3):535-544. doi: 10.1007/s10549-019-05420-8. Epub 2019 Aug 30.
20 CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?.Clin Cancer Res. 2020 Jan 1;26(1):3-5. doi: 10.1158/1078-0432.CCR-19-3119. Epub 2019 Nov 5.
21 Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.Oncotarget. 2017 Feb 21;8(8):12558-12575. doi: 10.18632/oncotarget.14894.
22 Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells.Cancer Res. 2007 Dec 1;67(23):11284-90. doi: 10.1158/0008-5472.CAN-07-2728.
23 Genome-wide association study of germline variants and breast cancer-specific mortality.Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.
24 Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.Cancer Lett. 2007 Jun 28;251(2):302-10. doi: 10.1016/j.canlet.2006.11.031. Epub 2007 Jan 9.
25 Estrogen alters the splicing of type 1 corticotropin-releasing hormone receptor in breast cancer cells.Sci Signal. 2013 Jul 2;6(282):ra53. doi: 10.1126/scisignal.2003926.
26 CRY2 is suppressed by FOXM1 mediated promoter hypermethylation in breast cancer.Biochem Biophys Res Commun. 2017 Aug 12;490(1):44-50. doi: 10.1016/j.bbrc.2017.06.003. Epub 2017 Jun 2.
27 Overexpression of CXXC5 is a strong poor prognostic factor in ER+ breast cancer.Oncol Lett. 2018 Jul;16(1):395-401. doi: 10.3892/ol.2018.8647. Epub 2018 May 7.
28 Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.Clin Drug Investig. 2020 Jan;40(1):25-32. doi: 10.1007/s40261-019-00842-0.
29 Liver receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism.Breast Cancer Res. 2013 Jun 20;15(3):R51. doi: 10.1186/bcr3443.
30 The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.Oncogene. 2019 Jul;38(28):5551-5565. doi: 10.1038/s41388-019-0817-3. Epub 2019 Apr 9.
31 ERR target genes are poor prognostic factors in Tamoxifen-treated breast cancer.J Exp Clin Cancer Res. 2015 May 15;34(1):45. doi: 10.1186/s13046-015-0150-9.
32 Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.Am J Hum Genet. 2016 Oct 6;99(4):903-911. doi: 10.1016/j.ajhg.2016.07.017. Epub 2016 Sep 15.
33 Enhanced motility of KGF-transfected breast cancer cells.Anticancer Res. 2006 Mar-Apr;26(2A):961-6.
34 Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.J Nucl Med. 2017 Sep;58(9):1401-1407. doi: 10.2967/jnumed.116.188011. Epub 2017 Mar 9.
35 HSD17B1 genetic variants and hormone receptor-defined breast cancer.Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2766-72. doi: 10.1158/1055-9965.EPI-07-2891.
36 Upregulation of HSF1 in estrogen receptor positive breast cancer.Oncotarget. 2016 Dec 20;7(51):84239-84245. doi: 10.18632/oncotarget.12438.
37 Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells.Cell Stress Chaperones. 2007 Winter;12(4):307-19. doi: 10.1379/csc-276.1.
38 erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.Breast Cancer Res. 2011 Sep 22;13(5):R93. doi: 10.1186/bcr3018.
39 Hormone-related pathways and risk of breast cancer subtypes in African American women.Breast Cancer Res Treat. 2015 Nov;154(1):145-54. doi: 10.1007/s10549-015-3594-x. Epub 2015 Oct 12.
40 LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.
41 Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.Oncotarget. 2017 May 16;8(20):33172-33184. doi: 10.18632/oncotarget.16566.
42 Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.Mol Endocrinol. 2014 Oct;28(10):1740-51. doi: 10.1210/me.2014-1147. Epub 2014 Aug 22.
43 Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.Oncogene. 2017 Mar 23;36(12):1745-1752. doi: 10.1038/onc.2016.327. Epub 2016 Sep 5.
44 PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.Eur J Cell Biol. 2017 Aug;96(5):469-475. doi: 10.1016/j.ejcb.2017.03.006. Epub 2017 Mar 21.
45 Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer.Breast Cancer Res. 2011 Jan 26;13(1):R10. doi: 10.1186/bcr2817.
46 Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011 Jan 28;286(4):2864-76. doi: 10.1074/jbc.M110.143271. Epub 2010 Nov 17.
47 Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.BMC Cancer. 2019 Jan 16;19(1):78. doi: 10.1186/s12885-018-5186-8.
48 Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium.Carcinogenesis. 2016 Oct;37(10):951-956. doi: 10.1093/carcin/bgw077. Epub 2016 Aug 1.
49 Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer.BMC Cancer. 2012 Dec 10;12:585. doi: 10.1186/1471-2407-12-585.
50 SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.J Biol Chem. 2011 Sep 9;286(36):31830-8. doi: 10.1074/jbc.M111.229518. Epub 2011 Jul 19.
51 Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells.Drug Metab Pharmacokinet. 2015 Apr;30(2):133-41. doi: 10.1016/j.dmpk.2014.10.005. Epub 2014 Nov 14.
52 Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model.Carcinogenesis. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.
53 Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance.Curr Med Sci. 2019 Dec;39(6):978-983. doi: 10.1007/s11596-019-2131-2. Epub 2019 Dec 16.
54 Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.
55 TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation.Oncogene. 2017 May 25;36(21):2991-3001. doi: 10.1038/onc.2016.453. Epub 2017 Jan 9.
56 Functional characterization of Trip10 in cancer cell growth and survival. J Biomed Sci. 2011 Feb 7;18:12.
57 Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer.J Breast Cancer. 2017 Dec;20(4):361-367. doi: 10.4048/jbc.2017.20.4.361. Epub 2017 Dec 19.
58 Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.Int J Cancer. 2009 Jun 15;124(12):2829-36. doi: 10.1002/ijc.24266.
59 Binding of anterior gradient 2 and estrogen receptor-: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.Cancer Lett. 2016 Jul 10;377(1):32-43. doi: 10.1016/j.canlet.2016.04.003. Epub 2016 Apr 7.
60 High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptorpositive breast cancer.Oncol Rep. 2019 Oct;42(4):1413-1421. doi: 10.3892/or.2019.7275. Epub 2019 Aug 12.
61 miR-125a-3p inhibits ER transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.FASEB J. 2018 Feb;32(2):588-600. doi: 10.1096/fj.201700461RR. Epub 2018 Jan 4.
62 A Mendelian randomization study of the effects of blood lipids on breast cancer risk.Nat Commun. 2018 Sep 27;9(1):3957. doi: 10.1038/s41467-018-06467-9.
63 (18)F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with (18)F-FDG PET/CT.Oncologist. 2019 Dec;24(12):e1277-e1285. doi: 10.1634/theoncologist.2019-0096. Epub 2019 Jul 23.
64 MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells.Oncogene. 2019 Jun;38(26):5239-5249. doi: 10.1038/s41388-019-0789-3. Epub 2019 Apr 10.
65 OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition.Cancer Manag Res. 2019 Aug 15;11:7721-7737. doi: 10.2147/CMAR.S208721. eCollection 2019.
66 Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31.
67 RSK4 inhibits breast cancer cell proliferation and invasion invitro, and is correlated with estrogen receptor upregulation in breast cancer.Oncol Rep. 2019 Dec;42(6):2777-2787. doi: 10.3892/or.2019.7328. Epub 2019 Sep 20.
68 Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.Clin Breast Cancer. 2017 Jun;17(3):e135-e142. doi: 10.1016/j.clbc.2016.11.005. Epub 2016 Nov 23.
69 Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.PLoS One. 2015 Jul 15;10(7):e0132269. doi: 10.1371/journal.pone.0132269. eCollection 2015.
70 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.Cancer Res. 2006 Dec 1;66(23):11471-7. doi: 10.1158/0008-5472.CAN-06-1448.
71 Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol. 2014 Jun;171(11):2705-25.
72 UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1.Oncotarget. 2017 Dec 22;9(9):8326-8333. doi: 10.18632/oncotarget.23608. eCollection 2018 Feb 2.
73 Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.Pharmacogenomics J. 2020 Feb;20(1):19-26. doi: 10.1038/s41397-019-0087-z. Epub 2019 Apr 10.
74 Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype.PLoS One. 2014 Feb 3;9(2):e87878. doi: 10.1371/journal.pone.0087878. eCollection 2014.
75 Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells.Biochem J. 2011 Jul 15;437(2):323-33. doi: 10.1042/BJ20101388.
76 Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.PLoS One. 2015 Aug 6;10(8):e0134351. doi: 10.1371/journal.pone.0134351. eCollection 2015.
77 The secretory small GTPase Rab27B as a marker for breast cancer progression.Oncotarget. 2010 Aug;1(4):304-308. doi: 10.18632/oncotarget.140.
78 miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.Mol Cancer. 2015 Jan 27;14:11. doi: 10.1186/s12943-014-0275-z.
79 ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.Breast Cancer Res. 2016 Nov 16;18(1):113. doi: 10.1186/s13058-016-0770-9.
80 Association study of susceptibility loci with specific breast cancer subtypes in Chinese women.Breast Cancer Res Treat. 2014 Aug;146(3):503-14. doi: 10.1007/s10549-014-3041-4. Epub 2014 Jul 10.
81 Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression.Am J Hum Genet. 2015 Jul 2;97(1):22-34. doi: 10.1016/j.ajhg.2015.05.002. Epub 2015 Jun 11.
82 Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.Clin Breast Cancer. 2020 Apr;20(2):131-144.e3. doi: 10.1016/j.clbc.2019.07.009. Epub 2019 Sep 3.
83 The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer.BMC Cancer. 2010 Apr 6;10:126. doi: 10.1186/1471-2407-10-126.
84 Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.PLoS One. 2019 Mar 15;14(3):e0209392. doi: 10.1371/journal.pone.0209392. eCollection 2019.
85 LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ER pathway.Nat Commun. 2018 Oct 9;9(1):4180. doi: 10.1038/s41467-018-06309-8.
86 The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.PLoS One. 2016 Aug 23;11(8):e0161731. doi: 10.1371/journal.pone.0161731. eCollection 2016.
87 Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.Nat Commun. 2018 Apr 23;9(1):1595. doi: 10.1038/s41467-018-03951-0.
88 BCAS2 Enhances Carcinogenic Effects of Estrogen Receptor Alpha in Breast Cancer Cells.Int J Mol Sci. 2019 Feb 22;20(4):966. doi: 10.3390/ijms20040966.
89 Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Cancer Sci. 2014 Jun;105(6):675-82. doi: 10.1111/cas.12410. Epub 2014 May 2.
90 Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.Nat Commun. 2014 Aug 7;5:4577. doi: 10.1038/ncomms5577.
91 The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.
92 Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.Breast Cancer Res. 2012 May 4;14(3):R72. doi: 10.1186/bcr3181.
93 Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer.Oncotarget. 2017 Jul 10;8(37):62167-62182. doi: 10.18632/oncotarget.19131. eCollection 2017 Sep 22.
94 Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.J Nanobiotechnology. 2018 Feb 20;16(1):17. doi: 10.1186/s12951-018-0345-2.
95 CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10.
96 Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer.Clin Exp Pharmacol Physiol. 2019 Sep;46(9):837-844. doi: 10.1111/1440-1681.13104. Epub 2019 Jun 10.
97 Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.Histol Histopathol. 2019 Dec;34(12):1365-1375. doi: 10.14670/HH-18-130. Epub 2019 May 31.
98 Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.Mol Cell Endocrinol. 2016 May 15;427:133-42. doi: 10.1016/j.mce.2016.03.012. Epub 2016 Mar 12.
99 DDX17 (P72), a Sox2 binding partner, promotes stem-like features conferred by Sox2 in a small cell population in estrogen receptor-positive breast cancer.Cell Signal. 2016 Feb;28(2):42-50. doi: 10.1016/j.cellsig.2015.11.004. Epub 2015 Nov 10.
100 Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer.Oncotarget. 2016 Aug 16;7(33):53204-53216. doi: 10.18632/oncotarget.10633.
101 NRF2 Induction Supporting Breast Cancer Cell Survival Is Enabled by Oxidative Stress-Induced DPP3-KEAP1 Interaction.Cancer Res. 2017 Jun 1;77(11):2881-2892. doi: 10.1158/0008-5472.CAN-16-2204. Epub 2017 Apr 17.
102 Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.Mol Cancer. 2017 Oct 17;16(1):161. doi: 10.1186/s12943-017-0727-3.
103 A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.Int J Oncol. 2018 Oct;53(4):1601-1612. doi: 10.3892/ijo.2018.4492. Epub 2018 Jul 19.
104 E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.Biomed Pharmacother. 2017 Aug;92:919-926. doi: 10.1016/j.biopha.2017.05.118. Epub 2017 Jun 8.
105 Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.PLoS One. 2018 Oct 2;13(10):e0204658. doi: 10.1371/journal.pone.0204658. eCollection 2018.
106 Estrogen receptor promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).J Biol Chem. 2019 Feb 15;294(7):2267-2278. doi: 10.1074/jbc.RA118.004383. Epub 2018 Dec 20.
107 The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.Cell Death Dis. 2015 Jan 22;6(1):e1603. doi: 10.1038/cddis.2014.542.
108 Overexpression of Epsin3 enhances migration and invasion of glioma cells by inducing epithelialmesenchymal transition.Oncol Rep. 2018 Nov;40(5):3049-3059. doi: 10.3892/or.2018.6691. Epub 2018 Sep 10.
109 EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.Oncotarget. 2016 Oct 25;7(43):69592-69605. doi: 10.18632/oncotarget.11870.
110 MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.Cell Physiol Biochem. 2018;48(2):461-474. doi: 10.1159/000491777. Epub 2018 Jul 17.
111 Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.EMBO Rep. 2019 Feb;20(2):e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.
112 An exome-wide analysis of low frequency and rare variants in relation to risk of breast cancer in African American Women: the AMBER Consortium.Carcinogenesis. 2016 Sep;37(9):870-877. doi: 10.1093/carcin/bgw067. Epub 2016 Jun 7.
113 FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.BMC Cancer. 2019 Apr 11;19(1):351. doi: 10.1186/s12885-019-5500-0.
114 Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase.Breast Cancer Res Treat. 2011 Nov;130(2):387-98. doi: 10.1007/s10549-010-1300-6. Epub 2010 Dec 29.
115 The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).BMC Cancer. 2019 Feb 28;19(1):187. doi: 10.1186/s12885-019-5373-2.
116 G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.Cell Cycle. 2017;16(21):2146-2155. doi: 10.1080/15384101.2017.1371884. Epub 2017 Sep 14.
117 First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.J Pathol. 2005 Jul;206(3):366-76. doi: 10.1002/path.1785.
118 Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.Cancer Lett. 2018 Oct 10;434:184-195. doi: 10.1016/j.canlet.2018.07.026. Epub 2018 Jul 21.
119 GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.Breast Cancer Res Treat. 2019 Feb;174(1):65-78. doi: 10.1007/s10549-018-5052-z. Epub 2018 Nov 19.
120 Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.
121 miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.Oncol Rep. 2017 Feb;37(2):1093-1099. doi: 10.3892/or.2017.5360. Epub 2017 Jan 9.
122 HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells.Int J Biol Sci. 2015 May 1;11(6):701-11. doi: 10.7150/ijbs.11431. eCollection 2015.
123 Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.Jpn J Clin Oncol. 2007 Aug;37(8):575-82. doi: 10.1093/jjco/hym066. Epub 2007 Aug 3.
124 Increased expression of estrogen receptor -36 by breast cancer oncogene IKK promotes growth of ER-negative breast cancer cells.Cell Physiol Biochem. 2013;31(6):833-41. doi: 10.1159/000350101. Epub 2013 Jun 7.
125 Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.Asian Pac J Cancer Prev. 2015;16(1):291-7. doi: 10.7314/apjcp.2015.16.1.291.
126 The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.Clin Epigenetics. 2016 Apr 14;8:38. doi: 10.1186/s13148-016-0205-6. eCollection 2016.
127 Modulation of estrogen related receptor alpha activity by the kinesin KIF17.Oncotarget. 2017 May 23;8(31):50359-50375. doi: 10.18632/oncotarget.18104. eCollection 2017 Aug 1.
128 Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+breast cancer.Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.
129 Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.Mol Cancer Res. 2014 Apr;12(4):539-49. doi: 10.1158/1541-7786.MCR-13-0459. Epub 2014 Jan 3.
130 MGP is downregulated due to promoter methylation in chemoresistant ER+ breast cancer and high MGP expression predicts better survival outcomes.Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3871-3878.
131 Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22.
132 Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.Breast Cancer Res Treat. 2019 Aug;177(1):77-91. doi: 10.1007/s10549-019-05307-8. Epub 2019 Jun 4.
133 Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer.EMBO Mol Med. 2012 Jan;4(1):52-67. doi: 10.1002/emmm.201100187. Epub 2011 Dec 15.
134 Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.J Proteome Res. 2016 Apr 1;15(4):1230-42. doi: 10.1021/acs.jproteome.5b01119. Epub 2016 Mar 18.
135 ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes and the Identification of ORAI3 as a Hypoxia Sensitive Gene and a Regulator of Hypoxia Responses.Cancers (Basel). 2019 Feb 11;11(2):208. doi: 10.3390/cancers11020208.
136 Targeted H3R26 deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure.PLoS Genet. 2014 Sep 11;10(9):e1004613. doi: 10.1371/journal.pgen.1004613. eCollection 2014 Sep.
137 Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical-only ER-positive breast cancer.J Cell Physiol. 2019 Jul;234(7):11140-11148. doi: 10.1002/jcp.27756. Epub 2018 Dec 7.
138 PHLDA1 expression is controlled by an estrogen receptor-NFB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres.Oncogene. 2015 Apr 30;34(18):2309-16. doi: 10.1038/onc.2014.180. Epub 2014 Jun 23.
139 Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium.Carcinogenesis. 2017 Aug 1;38(8):789-796. doi: 10.1093/carcin/bgx055.
140 PRMT2 and ROR expression are associated with breast cancer survival outcomes.Mol Endocrinol. 2014 Jul;28(7):1166-85. doi: 10.1210/me.2013-1403. Epub 2014 Jun 9.
141 Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.Cancer Sci. 2012 Jun;103(6):1121-8. doi: 10.1111/j.1349-7006.2012.02266.x. Epub 2012 Apr 12.
142 Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017.
143 RAI2: Linking Retinoic Acid Signaling with Metastasis Suppression.Cancer Discov. 2015 May;5(5):466-8. doi: 10.1158/2159-8290.CD-15-0352.
144 Phosphorylated Rasal2 facilitates breast cancer progression.EBioMedicine. 2019 Dec;50:144-155. doi: 10.1016/j.ebiom.2019.11.019. Epub 2019 Nov 21.
145 CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.Mol Cancer Res. 2007 Dec;5(12):1285-95. doi: 10.1158/1541-7786.MCR-07-0126.
146 Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status.Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. doi: 10.1002/mc.21979. Epub 2012 Nov 9.
147 Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer.Oncotarget. 2015 May 20;6(14):12264-78. doi: 10.18632/oncotarget.3654.
148 Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.J Natl Cancer Inst. 2018 Apr 1;110(4). doi: 10.1093/jnci/djx207.
149 RNF168 facilitates oestrogen receptor transcription and drives breast cancer proliferation.J Cell Mol Med. 2018 Sep;22(9):4161-4170. doi: 10.1111/jcmm.13694. Epub 2018 Jul 5.
150 Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.Cancer Biol Med. 2018 Feb;15(1):29-38. doi: 10.20892/j.issn.2095-3941.2017.0122.
151 MART-10, a 1,25(OH)(2)D(3) Analog, Potently Represses Metastasis of ER(+) Breast Cancer Cells with VEGF-A Overexpression.Anticancer Res. 2018 Jul;38(7):3879-3887. doi: 10.21873/anticanres.12672.
152 Aberrant expression of SETD1A promotes survival and migration of estrogen receptor -positive breast cancer cells.Int J Cancer. 2018 Dec 1;143(11):2871-2883. doi: 10.1002/ijc.31853. Epub 2018 Oct 4.
153 SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.Mol Endocrinol. 2011 Jan;25(1):72-82. doi: 10.1210/me.2010-0294. Epub 2010 Nov 17.
154 Small G protein signalling modulator 2 (SGSM2) is involved in oestrogen receptor-positive breast cancer metastasis through enhancement of migratory cell adhesion via interaction with E-cadherin.Cell Adh Migr. 2019 Dec;13(1):120-137. doi: 10.1080/19336918.2019.1568139. Epub 2019 Feb 11.
155 A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):735-745. doi: 10.1016/j.bbadis.2017.12.018. Epub 2017 Dec 14.
156 Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3816-25. doi: 10.1073/pnas.1510077112. Epub 2015 Jun 29.
157 A common variant in the SIAH2 locus is associated with estrogen receptor-positive breast cancer in the Chinese Han population.PLoS One. 2013 Nov 11;8(11):e79365. doi: 10.1371/journal.pone.0079365. eCollection 2013.
158 Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry.Mol Carcinog. 2017 Mar;56(3):1000-1009. doi: 10.1002/mc.22565. Epub 2016 Sep 21.
159 SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.Cancer Med. 2019 Nov;8(16):7086-7097. doi: 10.1002/cam4.2557. Epub 2019 Oct 1.
160 Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells.Am J Pathol. 2012 Mar;180(3):1189-1201. doi: 10.1016/j.ajpath.2011.11.025.
161 The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.BMC Cancer. 2015 Jun 19;15:474. doi: 10.1186/s12885-015-1445-0.
162 TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer.Cancers (Basel). 2019 Feb 12;11(2):210. doi: 10.3390/cancers11020210.
163 Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.Oncotarget. 2017 Jun 9;8(43):74188-74208. doi: 10.18632/oncotarget.18431. eCollection 2017 Sep 26.
164 ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression.Mol Cell Biol. 2019 Nov 12;39(23):e00261-19. doi: 10.1128/MCB.00261-19. Print 2019 Dec 1.
165 Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.Breast Cancer Res Treat. 2010 Nov;124(1):237-41. doi: 10.1007/s10549-010-0809-z. Epub 2010 Mar 9.
166 TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.Am J Pathol. 2012 Feb;180(2):839-47. doi: 10.1016/j.ajpath.2011.10.020. Epub 2011 Dec 2.
167 Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer.Cell Cycle. 2017 Feb 16;16(4):312-318. doi: 10.1080/15384101.2016.1237325. Epub 2017 Jan 5.
168 Downregulation of BAG? in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.Oncol Rep. 2019 Mar;41(3):1901-1910. doi: 10.3892/or.2019.6978. Epub 2019 Jan 22.
169 CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.Tumour Biol. 2017 Oct;39(10):1010428317722064. doi: 10.1177/1010428317722064.
170 KMT2C mediates the estrogen dependence of breast cancer through regulation of ER enhancer function.Oncogene. 2018 Aug;37(34):4692-4710. doi: 10.1038/s41388-018-0273-5. Epub 2018 May 14.
171 MASTL is a potential poor prognostic indicator in ER+ breast cancer.Eur Rev Med Pharmacol Sci. 2017 May;21(10):2413-2420.
172 Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.Cancer Lett. 2018 Apr 10;419:233-244. doi: 10.1016/j.canlet.2018.01.054. Epub 2018 Feb 2.